The global age-related macular degeneration (AMD) market reached a revenue of $5.3 billion in 2015 and it is predicted to attain a value of $8.9 billion by 2022. Furthermore, the market will demonstrate a CAGR of 7.6% from 2016 to 2022 (forecast period), as per the estimates of the market research firm, P&S Intelligence. The market is being driven by the increasing incidence of chronic diseases, surging healthcare expenditure in several countries, soaring pipeline of AMD drugs, and mushrooming population of geriatric people all over the world.

Access Report Summary Age-Related Macular Degeneration Market Segmentation Analysis Report@ https://www.psmarketresearch.com/market-analysis/age-related-macula...

With the rising costs of healthcare, on account of the increasing fees of physicians and soaring costs of advanced treatment procedures, the governments of many countries are augmenting their expenditure on healthcare in order to reduce the escalating healthcare burden on citizens. This is, in turn, making healthcare affordable and accessible to a large number of people, thereby supporting the growth of the market. Additionally, the expanding pipeline of AMD drugs is also driving the progress of the market.

Since geriatric people are highly vulnerable to visual impairment, their growing population is positively impacting the worldwide demand for AMD drugs. AMD is primarily the deterioration of the macula, which subsequently causes the loss of vision. Depending on type, the AMD market is bifurcated into dry AMD and wet AMD. Between these, the wet AMD category is predicted to register faster growth in the market during the forecast period. This will be because of the surging population of aging people and growing incidence of the ailment.

When drugs are taken into consideration, the AMD market is categorized into lucentis, avastin, visudyne, and eylea. Out of these, the lucentis category is predicted to dominate the market throughout the forecast period, accounting for as much as 50% of the shares in the market by 2022. Geographically, the market is currently being dominated by the North American region. This is ascribed to the rising incidence of medical conditions such as obesity and hypertension in the region.